S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:SILK

Silk Road Medical Competitors

$54.59
+1.45 (+2.73 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$52.10
Now: $54.59
$54.98
50-Day Range
$53.14
MA: $58.41
$62.70
52-Week Range
$20.84
Now: $54.59
$75.80
Volume389,682 shs
Average Volume384,390 shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41

Competitors

Silk Road Medical (NASDAQ:SILK) Vs. HRC, HAE, GMED, INSP, IART, and TNDM

Should you be buying SILK stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Silk Road Medical, including Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), and Tandem Diabetes Care (TNDM).

Hill-Rom (NYSE:HRC) and Silk Road Medical (NASDAQ:SILK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Institutional & Insider Ownership

83.8% of Hill-Rom shares are held by institutional investors. 0.7% of Hill-Rom shares are held by insiders. Comparatively, 7.8% of Silk Road Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Hill-Rom and Silk Road Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.88 billion2.47$223 million$5.5319.41
Silk Road Medical$63.35 million29.26$-52,420,000.00($1.36)-40.14

Hill-Rom has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Hill-Rom and Silk Road Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
Silk Road Medical02202.50

Hill-Rom currently has a consensus price target of $121.00, indicating a potential upside of 12.74%. Silk Road Medical has a consensus price target of $64.75, indicating a potential upside of 18.61%. Given Silk Road Medical's higher probable upside, analysts clearly believe Silk Road Medical is more favorable than Hill-Rom.

Profitability

This table compares Hill-Rom and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.74%22.71%8.01%
Silk Road Medical-53.66%-40.79%-24.56%

Volatility and Risk

Hill-Rom has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Summary

Hill-Rom beats Silk Road Medical on 10 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Silk Road Medical (NASDAQ:SILK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Haemonetics and Silk Road Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00503.00
Silk Road Medical02202.50

Haemonetics presently has a consensus target price of $144.80, suggesting a potential upside of 12.16%. Silk Road Medical has a consensus target price of $64.75, suggesting a potential upside of 18.61%. Given Silk Road Medical's higher probable upside, analysts plainly believe Silk Road Medical is more favorable than Haemonetics.

Valuation and Earnings

This table compares Haemonetics and Silk Road Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.64$76.53 million$3.3139.00
Silk Road Medical$63.35 million29.26$-52,420,000.00($1.36)-40.14

Haemonetics has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares Haemonetics and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Silk Road Medical-53.66%-40.79%-24.56%

Insider and Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by company insiders. Comparatively, 7.8% of Silk Road Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Haemonetics beats Silk Road Medical on 10 of the 14 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Silk Road Medical (NASDAQ:SILK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Insider & Institutional Ownership

64.4% of Globus Medical shares are held by institutional investors. 25.6% of Globus Medical shares are held by company insiders. Comparatively, 7.8% of Silk Road Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Globus Medical has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares Globus Medical and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Globus Medical12.36%9.85%9.04%
Silk Road Medical-53.66%-40.79%-24.56%

Analyst Recommendations

This is a breakdown of recent recommendations for Globus Medical and Silk Road Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Globus Medical041002.71
Silk Road Medical02202.50

Globus Medical currently has a consensus target price of $66.40, indicating a potential upside of 7.13%. Silk Road Medical has a consensus target price of $64.75, indicating a potential upside of 18.61%. Given Silk Road Medical's higher possible upside, analysts plainly believe Silk Road Medical is more favorable than Globus Medical.

Earnings & Valuation

This table compares Globus Medical and Silk Road Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$785.37 million7.79$155.21 million$1.6836.89
Silk Road Medical$63.35 million29.26$-52,420,000.00($1.36)-40.14

Globus Medical has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Globus Medical beats Silk Road Medical on 11 of the 14 factors compared between the two stocks.

Silk Road Medical (NASDAQ:SILK) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Silk Road Medical and Inspire Medical Systems' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silk Road Medical$63.35 million29.26$-52,420,000.00($1.36)-40.14
Inspire Medical Systems$82.05 million74.27$-33,240,000.00($1.40)-161.60

Inspire Medical Systems has higher revenue and earnings than Silk Road Medical. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Silk Road Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Silk Road Medical and Inspire Medical Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silk Road Medical02202.50
Inspire Medical Systems03802.73

Silk Road Medical currently has a consensus target price of $64.75, indicating a potential upside of 18.61%. Inspire Medical Systems has a consensus target price of $168.5455, indicating a potential downside of 25.50%. Given Silk Road Medical's higher possible upside, equities analysts plainly believe Silk Road Medical is more favorable than Inspire Medical Systems.

Profitability

This table compares Silk Road Medical and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silk Road Medical-53.66%-40.79%-24.56%
Inspire Medical Systems-61.07%-32.23%-26.42%

Risk & Volatility

Silk Road Medical has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.

Insider and Institutional Ownership

96.3% of Inspire Medical Systems shares are owned by institutional investors. 7.8% of Silk Road Medical shares are owned by insiders. Comparatively, 6.6% of Inspire Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Inspire Medical Systems beats Silk Road Medical on 8 of the 14 factors compared between the two stocks.

Silk Road Medical (NASDAQ:SILK) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings and price targets for Silk Road Medical and Integra LifeSciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silk Road Medical02202.50
Integra LifeSciences15502.36

Silk Road Medical presently has a consensus price target of $64.75, suggesting a potential upside of 18.61%. Integra LifeSciences has a consensus price target of $64.7273, suggesting a potential downside of 6.52%. Given Silk Road Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Silk Road Medical is more favorable than Integra LifeSciences.

Earnings & Valuation

This table compares Silk Road Medical and Integra LifeSciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silk Road Medical$63.35 million29.26$-52,420,000.00($1.36)-40.14
Integra LifeSciences$1.52 billion3.85$50.20 million$2.7425.27

Integra LifeSciences has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Silk Road Medical has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares Silk Road Medical and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silk Road Medical-53.66%-40.79%-24.56%
Integra LifeSciences4.10%14.26%5.77%

Insider and Institutional Ownership

85.7% of Integra LifeSciences shares are owned by institutional investors. 7.8% of Silk Road Medical shares are owned by insiders. Comparatively, 4.3% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Integra LifeSciences beats Silk Road Medical on 9 of the 14 factors compared between the two stocks.

Tandem Diabetes Care (NASDAQ:TNDM) and Silk Road Medical (NASDAQ:SILK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Earnings & Valuation

This table compares Tandem Diabetes Care and Silk Road Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$362.30 million15.97$-24,750,000.00($0.22)-431.77
Silk Road Medical$63.35 million29.26$-52,420,000.00($1.36)-40.14

Tandem Diabetes Care has higher revenue and earnings than Silk Road Medical. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Silk Road Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tandem Diabetes Care and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tandem Diabetes Care-11.10%-10.98%-5.59%
Silk Road Medical-53.66%-40.79%-24.56%

Institutional and Insider Ownership

88.6% of Tandem Diabetes Care shares are held by institutional investors. 6.0% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 7.8% of Silk Road Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Tandem Diabetes Care has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tandem Diabetes Care and Silk Road Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tandem Diabetes Care04902.69
Silk Road Medical02202.50

Tandem Diabetes Care currently has a consensus target price of $118.6154, indicating a potential upside of 24.87%. Silk Road Medical has a consensus target price of $64.75, indicating a potential upside of 18.61%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Silk Road Medical.

Summary

Tandem Diabetes Care beats Silk Road Medical on 10 of the 14 factors compared between the two stocks.


Silk Road Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Hill-Rom logo
HRC
Hill-Rom
2.0$107.33+0.6%$7.12 billion$2.88 billion32.33
Haemonetics logo
HAE
Haemonetics
1.6$129.10+1.2%$6.56 billion$988.48 million62.37
Globus Medical logo
GMED
Globus Medical
1.6$61.98+2.3%$6.12 billion$785.37 million67.37Analyst Report
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.4$226.24+2.2%$6.09 billion$82.05 million-97.52Earnings Announcement
Analyst Report
Analyst Revision
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.24+1.4%$5.84 billion$1.52 billion103.34Analyst Report
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.4$94.99+3.9%$5.79 billion$362.30 million-117.27Earnings Announcement
Analyst Report
News Coverage
Gap Down
Nevro logo
NVRO
Nevro
1.2$167.14+2.3%$5.75 billion$390.26 million-61.45Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inari Medical logo
NARI
Inari Medical
0.8$104.85+3.4%$5.11 billionN/A0.00Insider Selling
ICU Medical logo
ICUI
ICU Medical
1.3$218.19+0.6%$4.58 billion$1.27 billion57.72News Coverage
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$147.73+3.6%$4.27 billion$214.55 million-77.35Earnings Announcement
Glaukos logo
GKOS
Glaukos
0.9$92.11+4.7%$4.14 billion$236.98 million-55.82News Coverage
SWAV
ShockWave Medical
1.4$116.54+8.2%$3.99 billion$42.93 million-57.69Analyst Report
Insider Selling
Cantel Medical logo
CMD
Cantel Medical
1.3$73.39+0.0%$3.10 billion$1.02 billion87.37Upcoming Earnings
News Coverage
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$54.85+2.9%$3.05 billion$994.85 million-103.49Earnings Announcement
Analyst Report
News Coverage
NuVasive logo
NUVA
NuVasive
1.3$58.50+0.1%$3.00 billion$1.17 billion-265.91Earnings Announcement
AtriCure logo
ATRC
AtriCure
1.5$64.78+3.7%$2.92 billion$230.81 million-56.33Earnings Announcement
Analyst Report
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$11.49+4.5%$2.15 billion$4.11 million-8.45Upcoming Earnings
AXNX
Axonics Modulation Technologies
1.5$50.82+4.0%$2.02 billion$13.82 million-25.93Earnings Announcement
News Coverage
LUNG
Pulmonx
0.7$54.00+1.9%$1.93 billion$32.60 million0.00Upcoming Earnings
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$41.37+2.2%$1.66 billion$236.54 million-62.68
Luminex logo
LMNX
Luminex
1.8$32.99+8.9%$1.53 billion$334.64 million84.59High Trading Volume
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.4$18.80+2.6%$1.35 billion$88.02 million-45.85Earnings Announcement
Alphatec logo
ATEC
Alphatec
0.8$15.83+4.0%$1.24 billion$113.43 million-14.39Upcoming Earnings
Atrion logo
ATRI
Atrion
1.1$640.00+2.6%$1.19 billion$155.07 million36.06
MDXG
MiMedx Group
0.0$9.75+2.9%$1.08 billion$299.26 million-10.37News Coverage
Cerus logo
CERS
Cerus
1.5$6.45+4.2%$1.08 billion$74.65 million-16.54Earnings Announcement
High Trading Volume
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$54.62+2.2%$1.07 billion$72.55 million-37.93Upcoming Earnings
Analyst Downgrade
SIBN
SI-BONE
1.2$31.10+4.2%$1.01 billion$67.30 million-19.44
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$51.60+3.8%$1.00 billion$189.49 million-114.66Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
CryoLife logo
CRY
CryoLife
1.8$25.24+4.2%$980.75 million$276.22 million-66.42
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$46.45+2.6%$944.89 million$117.23 million49.95Earnings Announcement
News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$46.41+3.1%$897.29 million$459.95 million38.68
AngioDynamics logo
ANGO
AngioDynamics
1.4$20.45+0.3%$776.36 million$264.16 million-4.57
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.69+1.5%$766.83 million$154.60 million-46.48Upcoming Earnings
Intersect ENT logo
XENT
Intersect ENT
1.2$23.16+4.5%$757.77 million$109.14 million-12.13
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.47+0.2%$745.02 million$123.86 million74.51Upcoming Earnings
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$28.99+10.0%$734.67 millionN/A-12.77Earnings Announcement
Surmodics logo
SRDX
Surmodics
1.5$51.68+0.0%$710.91 million$94.86 million646.00Unusual Options Activity
News Coverage
VAPO
Vapotherm
1.5$23.17+16.6%$594.57 million$48.10 million-11.03Analyst Report
High Trading Volume
Gap Up
AFIB
Acutus Medical
1.5$20.90+3.3%$581.98 million$2.84 million0.00
SeaSpine logo
SPNE
SeaSpine
1.3$19.48+4.2%$538.29 million$159.08 million-11.66Upcoming Earnings
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$37.39+5.1%$531.50 million$114.51 million-79.55Upcoming Earnings
News Coverage
RCEL
AVITA Medical
1.4$23.29+7.8%$503.74 million$14.26 million-11.25News Coverage
Gap Up
Accuray logo
ARAY
Accuray
2.3$5.17+2.3%$479.82 million$382.93 million36.89
PROF
Profound Medical
1.5$21.57+7.7%$435.91 million$4.17 million-18.44Upcoming Earnings
Co-Diagnostics logo
CODX
Co-Diagnostics
1.7$15.40+8.3%$435.34 million$220,000.0019.01Gap Up
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.71+4.1%$419.24 million$24.95 million-29.42Upcoming Earnings
ICAD
iCAD
1.5$17.19+5.1%$395.25 million$31.34 million-18.09Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
CLPT
ClearPoint Neuro
1.2$21.64+9.8%$381.19 million$11.22 million-49.18Upcoming Earnings
Analyst Revision
Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.4$50.39+1.0%$377.67 million$198.38 million25.20Upcoming Earnings
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.